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Post-traumatic stress disorder (PTSD) is a common and serious psychiatric condition in the civilian
and veteran population. The lifetime prevalence of PTSD in the Canadian general population is
9.2%,1 which, surprisingly, is not significantly different from the 7.2% lifetime prevalence rate
within the Canadian Regular Forces.2 In Canadian veterans pensioned with a medical condition the
1-month prevalence was 10.3%.3 Given the serious functional impairment and impaired quality of
life4,5 associated with PTSD, careful assessment and treatment of PTSD is warranted. Due to the
complex clinical presentation of PTSD, which can include symptoms across the continuum from
adjustment disorder and subthreshold PTSD to “full-blown” PTSD, this issue of Mood and Anxiety
Disorders Rounds is confined to a general overview of the psychiatric management of PTSD with
comorbid psychiatric conditions. Despite the challenges researchers face in conducting studies on
the effectiveness of treatment of this disorder,6 if evidence-based practices are utilized using estab-
lished guidelines,7,8 remission can be achieved in 30%–50% of PTSD cases.9
Comorbidity: The Rule Rather Than the Exception
Over 90% of individuals with PTSD will have another Axis I disorder. Major depression,
another anxiety disorder (social phobia, generalized anxiety disorder, obsessive-compulsive
disorder, and panic disorder), alcohol and substance use disorders,10 and suicidality11 are common
comorbid conditions (Figure 1). Careful assessment for personality disorders, especially border-
line12 and antisocial,13 is required because Axis II pathology may substantially affect management.
Bipolar disorder is an important consideration, because bipolar II disorder is often difficult to
recognize and can be an important barrier to response to treatment. Emerging evidence shows a
strong relationship between PTSD and physical health problems.14,15 The most common medical
complaints associated with PTSD include chronic pain syndromes, asthma, gastrointestinal
complaints and cardiovascular disease.15,16 These conditions should be considered when planning
the management of PTSD. 
Psychiatric Assessment
The psychiatric assessment should detail the presenting symptoms and elicit a trauma history,
including childhood and adolescent trauma, and exposure to military trauma (combat or peace-
keeping operations).9 It should be noted that minute detail related to a traumatic event should only be
gathered if absolutely necessary; the recounting of an extremely traumatic event may be highly trig-
gering and lead to significant symptom exacerbation. If possible, history gathering should be limited
to information that clarifies the diagnosis. 
Post-traumatic Stress Disorder: Guiding
Management with Careful Assessment
of Comorbid Mental and Physical Illness 
By J. Don Richardson, MD, FRCPC, Diane McIntosh, MD, FRCPC, 
Murray B. Stein, MD, FRCPC, and Jitender Sareen, MD, FRCPC CANMAT Advisory Board Executive
Sagar V. Parikh, MD, FRCPC 
Education Chair, Toronto
Editor, Mood and Anxiety Disorders Rounds
sagar.parikh@uhn.on.ca
Sidney H. Kennedy, MD, FRCPC 
Depression Group Chair, Toronto
Raymond W. Lam, MD, FRCPC 
Executive Chair, Vancouver
Roger S. McIntyre, MD, FRCPC 
Business & Research Development Chair, 
Toronto
Arun Ravindran, MB, PhD, FRCPC 
Membership Chair, Toronto
Richard Swinson, MD
Anxiety Group Chair, Hamilton
Lakshmi N. Yatham, MBBS, FRCPC, 
MRCPsych (UK)
Bipolar Group Chair, Vancouver
CANMAT Board of Directors
Serge Beaulieu, MD, PhD, FRCPC 
Montréal
Marie-Josée Filteau, MD, MSc, FRCPC 
Québec City
Glenda MacQueen, MD, PhD, FRCPC 
Calgary
Roumen Milev, MD, PhD, FRCPsych (UK), FRCPC
Kingston
Claire O’Donovan, MD, FRCPC 
Halifax
Canadian Network for 
Mood and Anxiety Treatments
Education Office
Room 9M-329, Toronto Western Hospital 
399 Bathurst St, Toronto, On
CANADA  M5T 2S8
CANMAT – or the Canadian Network for Mood and
Anxiety Treatments – is a federally incorporated
academically based not-for-profit research
organization with representation from multiple
Canadian universities. The ultimate goal of
CANMAT is to improve the quality of life of
persons suffering from mood and anxiety
disorders, through conduct of innovative research
projects and registries, development of evidence
based and best practice educational programs
and guideline/policy development.
V O L U M E 1 ,  I S S U E 1
C U R R E N T  C L I N I C A L  T O P I C S  F R O M  L E A D I N G  R A  S P E C I A L I S T S  A C R O S S  C A N A D A  A N D  A R O U N D  T H E
W O R L D  I N V I T E D  B Y  T H E  R E B E C C A  M A C D O N A L D  C E N T R E  F O R  A R T H R I T I S  A N D  A U T O I M M U N E  D I S E A S E
V O L U M E 1 ,  I S S U E 1
A PHYSICIAN LEARNING RESOURCE FROM THE CANADIAN NETWO K FOR MOOD AND ANXIETY TREATMENTS
2 0 10 V O L U M E 1 ,  I S S U E 6  





Few debts are greater than those due to our military, who serve to keep us all safe. This issue is
devoted to PTSD, an affliction common in returning veterans; CANMAT wishes to express its
gratitude to the Canadian Armed Forces and hopes that this newsletter will be helpful to clini-
cians as they treat veterans and their families.
Patients with PTSD present with 4 symptom clusters: re-expe-
riencing the traumatic events, avoidance of reminders, emotional
numbing, and hyperarousal symptoms.7,17 Avoidance of reminders
and emotional numbing are grouped together as a symptom
cluster in the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV),17 but are seen as distinct and
will likely be denoted as such in DSM-V. Patients may relive their
trauma via intrusive recollections during the day, including flash-
backs, or at night as bad dreams or nightmares. Many complain of
both physical and emotional symptoms of anxiety when exposed
to reminders of their traumatic event. They may avoid reminders
of the trauma and describe emotional numbness or an inability to
experience a normal range of emotions. Common hyperarousal
symptoms include insomnia, irritability, poor concentration, and
hypervigilance. According to the DSM-IV-TR, acute PTSD has a
duration of 1–3 months, and the disorder is considered to be
chronic if its duration exceeds 3 months.17
The Primary Care PTSD Screen, a 4-item self-report yes/no
instrument, is easy to use in clinical practice. The instrument has a
sensitivity of 78% and specificity of 87% for PTSD in patients who
answer ‘yes’ to ≥3 items (Table 1).18 Patients who screen positive
should be assessed for PTSD using the DSM-IV-TR diagnostic
criteria, or by using a more specific screening instrument. The
Clinician Administered PTSD Scale (CAPS)19 may be too detailed
for most clinicians and is more commonly used in research centres.
A more practical approach is to use a self-rating scale such as the
PTSD Checklist, which has a military and a civilian version,20 and
then to confirm the self-report rating and the nature of the trau-
matic experience(s) with a clinical interview. Some patients may
present with some symptoms of PTSD without meeting the full
diagnostic criteria.21,22 Even if the full criteria are not met, studies
indicate that these individuals may experience significant func-
tional impairment,23 and may also benefit from treatment. 
Determining the presence of psychiatric comorbidity, as part
of a thorough PTSD assessment, is critical.23 PTSD often presents
with comorbidities such as depression and substance abuse and
dependence.10,24 Studies have estimated that >50% of PTSD
patients have symptoms of a major depressive disorder,10 but in
the veteran population the percentage may be much higher.25,26
A risk assessment for both suicidal and homicidal ideation is
essential. The presence of PTSD increases suicidal ideation and
the risk of completed suicide.11,23 The presence of comorbid
depression further increases suicide risk.11,27 In the veteran popu-
lation, aggression and anger are well documented.24,28 During the
initial PTSD assessment, military members may report violent
thoughts and aggressive behaviour, including homicidal thoughts.
Assessing comorbidity, suicidal or homicidal ideation, and extent
of social support is imperative in order to determine the need for
urgent, inpatient treatment.7 In particular, a high risk for suicidal
behaviour should prompt strong consideration for inpatient
admission. Enquiry should also be made into family functioning
as the family plays an important role in the treatment process.7
Treatment
Table 2 describes the initial steps in the management of
PTSD. Substantial comorbidities, whether psychiatric or phys-
ical, should be managed simultaneously with the PTSD. 
Psychoeducation
Once a firm diagnosis has been established, psychoeducation
regarding diagnosis and treatment is critical for both patients and
Figure 1: Important comorbid conditions to consider in












CASE 1: Military-related PTSD with physical injury and depression
A 27-year-old veteran was referred with persistent depressed mood, insomnia, and panic attacks. He was nonresponsive to citalo-
pram 30 mg daily. He was recently released from the Canadian Forces (CF) after serving 8 years. He first noticed symptoms after
returning home from his deployment in Afghanistan where he was exposed to major combat. He was the driver in the second
vehicle of a convoy when the lead vehicle hit a roadside bomb. He tried to rescue his comrade from the burning vehicle, but
they were ambushed by the Taliban. During the firefight he was shot in his right leg; he was evacuated first to the Kandahar
Airbase and was transferred to an American hospital in Germany, then back to Canada. 
Within 6 months of returning to Canada, the patient reported reliving the events in Afghanistan in intrusive recollections and
recurrent nightmares. He became preoccupied with the safety of his family, especially his children. He started to fear going to
bed and was drinking increasing amounts of alcohol to help him sleep and smoking marijuana to control pain. He started to
become nervous in crowds and became afraid to leave his home. He was irritable, frequently getting into fights at work and at
home with his wife. His moods were low; he had lost interest in most activities and complained of fatigue, low energy, diminished
appetite, and no sex drive. After his release from the military, he finally went to see his family doctor who started him on citalo-
pram and zopiclone to help him sleep. At first he noticed some improvement in anxiety, but these periods were short-lived. He
continued to use alcohol regularly for sleep and he was still having frequent anger outbursts. Finally, after losing his job and
reporting increased thoughts of suicide, his family doctor convinced him to see a psychiatrist. 
Following a comprehensive psychiatric evaluation, the initial plan was to focus on stabilization by aggressively treating his
comorbid addiction and major depression. An initial first step, as the patient was concerned with potential sexual side effects,
was to add bupropion XL 150 mg in combination with citalopram and start low-dose (15 mg) mirtazapine RD at bedtime to
assist with his sleep. He was also provided with extensive psychoeducation and psychotherapy focussing on depression and
addiction. Once his symptoms were better controlled, he could benefit from trauma-focussed psychotherapy.
dual-acting antidepressants should also be considered as first-line
treatments, especially in PTSD with comorbid major depression. 
Benzodiazepines are not recommended as monotherapy for
the treatment of PTSD,9,42,43 but are sometimes used for the treat-
ment of insomnia7 or, in combination with an antidepressant, to
treat acute anxiety. They might also be useful to manage early
side effects associated with some antidepressants or antipsy-
chotics, including restlessness, jitteriness, or agitation. There is a
risk of rebound insomnia or anxiety when a benzodiazepine is
discontinued, especially after long-term use.44 The use of benzo-
diazepines among patients with PTSD who have comorbid
substance abuse should be avoided.
Combining psychotherapy and pharmacotherapy
Although there is limited research evaluating combination
treatment,45,46 many clinicians prescribe psychotherapy and
pharmacotherapy either concurrently or sequentially during the
course of treatment. There is also evidence that psychotherapy
improves outcomes in patients with chronic PTSD who have
demonstrated a partial response to pharmacotherapy.47
Assessing treatment response
Despite the lack of a generally accepted definition for recovery
or remission in PTSD, assessing treatment response remains crit-
ical. Response to treatment for PTSD can be assessed objectively,
using the self-rated PTSD Checklist (Military or Civilian Version)
and comorbid depression can be assessed objectively using the
Hamilton rating scale for Depression (HAMD-7)48 or the self-
rated Patient Health Questionnaire (PHQ-9).49
Dosing considerations
PTSD patients often present with marked anxiety, and they
may be very sensitive to the potential heightened anxiety or
agitation sometimes associated with early antidepressant treat-
ment. Patients benefit from a “start low, go slow” approach to
medication titration. Consider initiating treatment at 25%–50%
of the usual starting dose and then gradually increasing to a ther-
apeutic level.50,51 While the initiation of medication might be
slow and cautious, ultimately the dose should be titrated to full
symptom remission, at maximum tolerated doses. 
Treatment adherence/compliance
Medication compliance is crucial for treatment to be effective.
False beliefs or fears about medications should be explored and
their families. Educating patients regarding the phases of treatment
and understanding of what is to be expected, particularly when to
expect treatment benefits, helps to avoid frustration and hopeless-
ness associated with inappropriate treatment expectations. 
Symptom stabilization
The main goal of stabilization is to manage acute symptoms
and improve current functioning. Stabilization usually requires
psychoeducation, anxiety management training, and medication
(Table 3). Once symptoms stabilize, patients are more able to
engage in psychotherapy,29 such as prolonged exposure and other
evidence-based forms of cognitive behavioural psychotherapy
(CBT). Regardless of the treatment modality, stabilization is criti -
cal. The initiation of “trauma-focussed psychotherapy” prior to
stabilization may exacerbate both PTSD symptoms and pre-
existing or comorbid symptoms of depression and substance abuse. 
For mild to moderate PTSD without significant comorbidity,
and where minimal stabilization is required, CBT may be initi-
ated prior to medication. However, for the typically more severe
and chronic cases referred to psychiatrists, CBT should follow
acute symptom stabilization with medication. CBT requires the
ability to learn and apply new information. When severe depres-
sion or anxiety symptoms are present, cognitive impairment is
common and often has a significant impact on new learning.
CBT specifically for PTSD typically involves close to 20 sessions
emphasizing a combination of cognitive restructuring of
maladaptive trauma-related beliefs and exposure techniques.30
Pharmacological management
As demonstrated in Table 3, a number of medications have
been employed to treat PTSD. Selective serotonin reuptake
inhibitors (SSRIs) and the serotonin norepinephrine reuptake
inhibitor (SNRI) venlafaxine have the most empirical evidence
for efficacy in the treatment of PTSD and are usually considered
as a first-line treatment for PTSD.7,31-35 SSRIs and venlafaxine are
also effective agents for the treatment of comorbid mood and
anxiety disorders commonly associated with PTSD. Education
about the potential risk of increased suicidal thoughts associated
with antidepressant medication, particularly at the time of initi-
ation of treatment, should also be reviewed with the patient.31
Other dual acting antidepressants such as mirtazapine, bupro-
pion, and, more recently, duloxetine are widely used to treat major
depression and other anxiety disorders, but have less empirical data
demonstrating their efficacy for the specific treatment of PTSD.36-
40 In PTSD they are considered as second- and third-line treatment
options for patients who have failed to respond to first-line treat-
ment. However, since SSRIs have not demonstrated their efficacy
in subpopulations of combat-related PTSD32,41 and due to the high
rate of comorbid major depression and other anxiety disorders,
Table 1: Primary Care PTSD Screen18
In your life, have you ever had any experience that was so
frightening, horrible, or upsetting that, in the past month, you:
1. Have had nightmares about it or thought about it when
you did not want to? 
2. Tried hard not to think about it or went out of your way
to avoid situations that reminded you of it? 
3. Were constantly on guard, watchful, or easily startled?
4. Felt numb or detached from others, activities, or your
surroundings? 
Screen is positive if patient answers “yes” to any three items.
Table 2: Important principles in the management of
PTSD
1. Develop a therapeutic alliance
2. Assess the safety and suicide risk
3. Consider the setting of treatment (outpatient, inpatient, or
day program) 
4. Assess and manage physical conditions that could 
exacerbate PTSD symptoms (eg, thyroid problems, chronic
pain conditions)
5. Conduct careful psychoeducation related to PTSD
6. If there is a current comorbidity (eg, substance use disorder,
mood disorder, or borderline personality disorder), prioritize
treatment of this/these condition(s)
7. Choose pharmacotherapy based on the presence of any
comorbidities
8. Once the comorbid condition(s) has/have been stabilized,
then consider a trauma-focussed cognitive behaviour therapy.
confronted prior to starting treatment and addressed regu-
larly during treatment follow-up. Providing a safe environ-
ment and a positive doctor-patient interaction will help
develop trust and improve medication compliance.52,53
Engaging and educating all care providers, including the
family, is essential. Peer social support programs can play a
valuable role in encouraging treatment adherence.54
Patients may wish to discontinue their medication once
they start to feel better or can no longer tolerate side effects
such as weight gain or sexual dysfunction. However, studies
have demonstrated that patients with PTSD continued to
show improvement with pharmacotherapy up to 36 weeks
after treatment initiation and early discontinuation leads to
a high rate of relapse.55 Therefore, in most cases, long-term
medication treatment may be recommended.45
There are no published guidelines specifying the length
of pharmacological treatment for anxiety disorders; however,
existing guidelines for major depression suggest that the
medication should be continued for at least 6 months to 1
year after symptom remission has been reached.56
Managing treatment-resistant PTSD
In cases of treatment-resistant PTSD, it is important to
reassess the patient to ensure that the diagnosis is correct
and that comorbid conditions have been considered in the
management. Although there is no treatment algorithm for
the pharmacological treatment of PTSD, for patients who
demonstrate a partial response (25%–50% improvement)
after 6-8 weeks of treatment with the first antidepressant
trial, optimization of monotherapy is a critical first step.
This generally entails titrating the agent to maximally toler-
ated doses, so long as each dose increase produces some
benefit. If after dose optimization a response to treatment
(≥50% improvement) is not evident, the initial agent
should be switched to another first-line agent. If optimizing
the initial agent leads to treatment response but not full
remission, combination strategies may be considered. There
is some evidence to suggest that combining 2 agents early
in the treatment of depression might be more effective than
monotherapy to induce remission,57 but it is unclear if this
strategy would be similarly effective in PTSD.
When considering combination strategies, discuss
potential risks as well as expected benefits with the patient.50
Common combination treatments include adding an anti-
depressant with a different mechanism (eg, mirtazapine or
bupropion) to an SSRI or SNRI. The utility of adding an
atypical antipsychotic (eg, risperidone, quetiapine, aripipra-
zole, or olanzapine) in combination with a primary antide-
pressant has been suggested in several small studies.58-61
These agents appear to be beneficial in managing hyper-
arousal symptoms such as hypervigilance and irritability, as
well as for severe dissociation symptoms.32 There is signifi-
cant evidence for the addition of an atypical antipsychotic
for treatment-resistant depression,62 which often presents as
a complicating factor in PTSD. There is no established role
for the use of conventional antipsychotics in the treatment
of PTSD. 
Anticonvulsant medications (eg, carbamazepine,
valproate, topiramate, and lamotrigine) are increasingly
used in combination with antidepressants to treat symp-
toms of depression, mood instability, and impulsivity;63-68
however, controlled trials have, to date, failed to confirm
the utility of these agents for PTSD.69 These agents are
generally reserved as third-line agents, and used in combi-
nation with first- or second-line agents. 
Insomnia is extremely common, persistent, and severe
for most PTSD patients. If symptoms of insomnia persist
with the use of therapeutic doses of antidepressants, a trial
of low-dose mirtazapine (15 mg) or trazodone (50-100 mg)
may be helpful. Alternative non-benzodiazepine hypnotics
First line Fluoxetine, paroxetine, sertraline,
venlafaxine XR
Second line Fluvoxamine, mirtazapine,
moclobemide, phenelzine
Adjunctive: risperidone, olanzapine








Not recommended Despipramine, cyproheptadine
Monotherapy: alprazolam,
clonazepam, olanzapine
Table 3: Recommendations for PTSD 
pharmaco therapy
CASE 2: PTSD with social phobia
A 28-year-old single woman was referred for assessment of anxiety symptoms. She described worrying throughout the
day, and was experiencing nightmares and concentration problems. She had experienced intimate-partner violence from
her ex-boyfriend, who had hit her and forced her to have sex with him on a number of occasions. She reported night-
mares about these attacks. She could not sleep in her own bedroom, where the attacks had occurred. The anxiety symp-
toms were so disabling she had difficulty functioning at work. She also described a long history of being shy and
described high anxiety in social situations. She was not suicidal, and denied a history of drug or alcohol abuse. Her
mother had life-long social phobia. There was no childhood history of sexual or physical abuse. 
The patient was treated with a combination of pharmacotherapy and psychotherapy. She responded to individual cogni-
tive behaviour therapy with a focus on exposure and response prevention. She also found that the anxiety symptoms
were substantially reduced with a combination of venlafaxine XR 300 mg per day, trazodone 25 mg at bedtime, and clon-
azepam 1 mg at bedtime. This approach not only improved the PTSD symptoms, but also reduced her social phobia.
With her symptoms of anxiety better controlled, the patient was now ready for trauma-focussed psychotherapy.
Reproduced with permission from the Canadian Psychiatric Association
Clinical Guidelines. Can J Psychiatry. 2006(5(Suppl 2):61S.
include zopiclone. There is also some evidence demon-
strating the benefits of using prazosin, an adrenergic
inhibitor specifically to reduce nightmares.70,71 A sleep study
should also be considered in cases where a specific
comorbid sleep disorder such as sleep apnea is suspected.
Conclusion
The presentation of PTSD is often complicated by
comorbidity. Understanding the impact of trauma can help
the clinician appreciate the challenges faced by the patient,
which is essential to establishing a trusting therapeutic
alliance. Treatment often involves a combination of
medications, making compliance more challenging.
Although remission is not always possible, pharmacological
interventions assist with symptom reduction and improve
functioning and quality of life. Pharmacological interven-
tions, especially with comorbidity, can also assist with stabi-
lization and facilitate psychotherapeutic interventions such
as trauma-focussed psychotherapy. 
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